174 related articles for article (PubMed ID: 38222984)
1. Successful Treatment of Eosinophilic Granulomatosis With Polyangiitis: A Case of Refractory Peripheral Neuropathy and Comorbid Chronic Progressive Pulmonary Aspergillosis Treated With Mepolizumab.
Sekiya R; Soma T; Nakagome K; Nagata M
Cureus; 2024 Jan; 16(1):e52192. PubMed ID: 38222984
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
3. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
4. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
[TBL] [Abstract][Full Text] [Related]
5. A case of subarachnoid haemorrhage associated with MPO-ANCA-positive eosinophilic granulomatosis with polyangiitis, successfully treated with glucocorticoid, cyclophosphamide, and mepolizumab.
Satake Y; Sakai S; Takao T; Saeki T
Mod Rheumatol Case Rep; 2023 Dec; ():. PubMed ID: 38109745
[TBL] [Abstract][Full Text] [Related]
6. Improvement of peripheral neuropathy in a patient with antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis by additional mepolizumab.
Kai Y; Yoshikawa M; Matsuda M; Suzuki K; Ohara H; Iguchi N; Kasamatsu T; Uno K; Fujioka N; Fujita Y; Muro S
Allergy Asthma Clin Immunol; 2022 Feb; 18(1):14. PubMed ID: 35183225
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report.
Toscano Peña A; Ali Munive A; Arevalo Y
Cureus; 2023 May; 15(5):e38797. PubMed ID: 37303316
[TBL] [Abstract][Full Text] [Related]
8. Anti-cytokine targeted therapies for ANCA-associated vasculitis.
Bala MM; Malecka-Massalska TJ; Koperny M; Zajac JF; Jarczewski JD; Szczeklik W
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD008333. PubMed ID: 32990324
[TBL] [Abstract][Full Text] [Related]
9. Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
Tsioulos G; Kounatidis D; Vallianou NG; Koufopoulos N; Katsimbri P; Antoniadou A
Am J Med Sci; 2023 Jan; 365(1):93-98. PubMed ID: 35970248
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
11. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement.
Afiari A; Gabriel A; Gaiki MR
Cureus; 2020 Jul; 12(7):e9242. PubMed ID: 32821588
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV.
Sanchez-Alamo B; Schirmer JH; Hellmich B; Jayne D; Monti S; Tomasson G; Luqmani RA
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37349121
[TBL] [Abstract][Full Text] [Related]
14. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report.
Suzaki I; Tanaka A; Yanai R; Maruyama Y; Kamimura S; Hirano K; Kobayashi H
BMC Pulm Med; 2023 Apr; 23(1):130. PubMed ID: 37076824
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
Ennis D; Lee JK; Pagnoux C
Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
[TBL] [Abstract][Full Text] [Related]
17. Eosinophilic Granulomatosis with Polyangiitis: Latest Findings and Updated Treatment Recommendations.
Watanabe R; Hashimoto M
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762936
[TBL] [Abstract][Full Text] [Related]
18. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
19. [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
Hellmich B; Holle J; Moosig F
Z Rheumatol; 2022 May; 81(4):286-299. PubMed ID: 35075511
[TBL] [Abstract][Full Text] [Related]
20. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
